Evidence map›Paper›PMID 22740640›Full record

ArticleMolecular pharmacology2012

Activator protein-1 regulation of murine aldehyde dehydrogenase 1a1.

N L Makia, I Amunom, K C Falkner, D J Conklin, S Surapureddi, J A Goldstein, R A Prough

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Experimental biology and medicine (Maywood, N.J.) · 2022
    Article
  4. Article
  5. DKK1 maintained cancer stem-like properties of esophageal carcinoma cells via ALDH1A1/SOX2 axis.International journal of clinical and experimental pathology · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Enzymatic intracrine regulation of white adipose tissue.Hormone molecular biology and clinical investigation · 2014
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

N L MakiaDepartment of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, Kentucky, USA.
I Amunom
K C Falkner
D J Conklin
S Surapureddi
J A Goldstein
R A Prough
National Institute of Environmental Health Sciences · USUniversity of Louisville · US

Funding

Drug Metabolizing Enzymes In Humans And Animal ModelsZIAES021024 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GOLDSTEIN, JOYCE · 2009 to 2015
$11.0M
Role of Platelet Activation and Vascular Pathology in Aldehyde ToxicityP01ES011860 · NIEHS · UNIVERSITY OF LOUISVILLE · PI BHATNAGAR, ARUNI BHATNAGAR · 2003 to 2007
$7.0M
Cardioprotective Mechanisms of Glutathione S-transferase PR01HL089380 · NHLBI · UNIVERSITY OF LOUISVILLE · PI CONKLIN, DANIEL JOSEPH · 2008 to 2012
$2.1M
NHLBI NIH HHS HL89380NHLBI NIH HHS R01 HL089380NIEHS NIH HHS ES11860NIEHS NIH HHS P01 ES011860
6 · The paper itself

Abstract

Previously we demonstrated that aldehyde dehydrogenase (ALDH) 1a1 is the major ALDH expressed in mouse liver and is an effective catalyst in metabolism of lipid aldehydes. Quantitative real-time polymerase chain reaction analysis revealed a ≈2.5- to 3-fold induction of the hepatic ALDH1A1 mRNA in mice administered either acrolein (5 mg/kg acrolein p.o.) or butylated hydroxylanisole (BHA) (0.45% in the diet) and of cytosolic NAD⁺-dependent ALDH activity. We observed ≈2-fold increases in ALDH1A1 mRNA levels in both Nrf2⁺/⁺ and Nrf2⁻/⁻ mice treated with BHA compared with controls, suggesting that BHA-induced expression is independent of nuclear factor E2-related factor 2 (Nrf2). The levels of activator protein-1 (AP-1) mRNA and protein, as well as the amount of phosphorylated c-Jun were significantly increased in mouse liver or Hepa1c1c7 cells treated with either BHA or acrolein. With use of luciferase reporters containing the 5'-flanking sequence of Aldh1a1 (-1963/+27), overexpression of c-Jun resulted in an ≈4-fold induction in luciferase activity, suggesting that c-Jun transactivates the Aldh1a1 promoter as a homodimer and not as a c-Jun/c-Fos heterodimer. Promoter deletion and mutagenesis analyses demonstrated that the AP-1 site at position -758 and possibly -1069 relative to the transcription start site was responsible for c-Jun-mediated transactivation. Electrophoretic mobility shift assay analysis with antibodies against c-Jun and c-Fos showed that c-Jun binds to the proximal AP-1 site at position -758 but not at -1069. Recruitment of c-Jun to this proximal AP-1 site by BHA was confirmed by chromatin immunoprecipitation analysis, indicating that recruitment of c-Jun to the mouse Aldh1a1 gene promoter results in increased transcription. This mode of regulation of an ALDH has not been described before.

Indexed as

AcroleinAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyAnimalsButylated HydroxyanisoleCell Line, TumorGene Expression RegulationHepatocytesHumansJNK Mitogen-Activated Protein KinasesLiverMaleMiceMice, Inbred C57BLMice, KnockoutMutagenesis, Site-DirectedAcroleinAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, mouseButylated HydroxyanisoleJNK Mitogen-Activated Protein KinasesNfe2l2 protein, mouseNF-E2-Related Factor 2Nuclear ProteinsProto-Oncogene Proteins c-junRetinal DehydrogenaseRNA, MessengerTranscription Factor AP-1

Identifiers

PMID22740640
PMCPMC3463228
OpenAlexW2098928236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.